Therefore, cellular BCMA-CD38-CAR-T cell therapy is feasible in treating patients with relapsed and refractory multiple myeloma (r/r MM), with high response rate, low recurrence rate and manageable CRS [43]. The gene discussed is CD38; the disease is plasma cell myeloma.